Enhancement of NETosis by ACE2-cross-reactive anti-SARS-CoV-2 RBD antibodies in patients with COVID-19.
Kun-Han HsiehChiao-Hsuan ChaoYi-Ling ChengYen-Chung LaiYung-Chun ChuangJen-Ren WangSui-Yuan ChangYuan-Pin HungYi-Ming Arthur ChenWei-Lun LiuWoei-Jer ChuangTrai-Ming YehPublished in: Journal of biomedical science (2024)
Our findings provide possible pathogenic effects of CR Abs in exacerbating COVID-19 by enhancing NETosis, highlighting ACE2 and dasatinib as potential treatments, and supporting the benefit of vaccination in reducing disease severity and CR Abs production in COVID-19 patients.